From the Journals

Uptick in lung cancer in younger women, not related to smoking


 

  • Individuals aged 30-34 years in Canada, Denmark, and Germany.
  • Those aged 40-44 years in Germany, the Netherlands, and the United States.
  • Those aged 44-50 years in the Netherlands and the United States.
  • Those aged 50-54 years in Canada, Denmark, and New Zealand.

Countries with an insignificant crossover from male to female dominance of lung cancer were located across Africa, the Americas, Asia, Europe, and Oceania.

Again, incidence rates were typically characterized by falling rates of lung cancer among men in more recent birth cohorts, and lung cancer incidence trends were more variable in women.

The team writes: “Of note, the six countries demonstrating a significant crossover are among those considered to be more advanced in the tobacco epidemic.

“Many of the countries where the crossover was insignificant or when there was no crossover are considered to be late adopters of the tobacco epidemic, with the effects of the epidemic on the burden of lung cancer and other smoking-related diseases beginning to manifest more recently, or perhaps yet to come.”

They suggest that low- and middle-resource countries may not follow the tobacco epidemic pattern of high-income countries, and so “we may not see higher lung cancer incidence rates in women than men for the foreseeable future in these countries.”

No funding for the study has been disclosed. The authors have disclosed no relevant financial relationships.

This article first appeared on Medscape.com.

Pages

Recommended Reading

Benefits and drawbacks found for risk-based lung cancer screening tools
MDedge Hematology and Oncology
Standard-dose RT with concurrent chemo found superior for unresectable NSCLC
MDedge Hematology and Oncology
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
MDedge Hematology and Oncology
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
MDedge Hematology and Oncology
‘Simple’ model predicts severe neutropenia risk in lung cancer patients
MDedge Hematology and Oncology
RCT confirms CT scan screening catches lung cancer early
MDedge Hematology and Oncology
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
MDedge Hematology and Oncology
Walk test may predict complications after lung cancer surgery
MDedge Hematology and Oncology
Global project reveals cancer’s genomic playbook
MDedge Hematology and Oncology
New tools could help predict complication risks in lung and breast cancer
MDedge Hematology and Oncology